Anticholinergic Drugs in Nonallergic Rhinitis by Robert Naclerio
NAR CONSENSUS PANEL PROCEEDINGS, PART 2
Anticholinergic Drugs in Nonallergic Rhinitis
Robert Naclerio, MD
Background: The parasympathetic nervous system contributes to
the pathophysiology of multiple forms of allergic and nonallergic
rhinitis. Stimulation of the parasympathetic nervous system leads to
glandular activation, which produces watery secretions. In excess,
these secretions discharge from the anterior Nares and produce the
symptom of watery anterior rhinorrhea.
Method: Review of literature.
Results: Treatment with topical, intranasal anticholinergic drugs
inhibits activation of the nasal mucosal glands and is effective in
reducing the watery secretions associated with parasympathetic
stimulation of the glands with little, if any, effect on the symptoms
of congestion and sneezing. In general, these drugs have no systemic
adverse effects, but can cause crusting and local irritation.
Conclusion: Anticholinergic drugs are useful for the treatment of
anterior rhinorrhea associated with allergic and nonallergic rhinitis.
Key Words: anticholinergic, atropine, ipratropium bromide,
rhinitis, nonallergic rhinitis
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INTRODUCTION
The nervous system plays an important role in nasal phys-iology and pathophysiology by functioning to provide
rapid responses to physical and chemical stimuli. The sen-
sory, parasympathetic, and sympathetic systems all contribute
to these responses. Up-regulation of this system can occur at
any level and is referred to as neural hyperresponsiveness.
Central neuronal reflexes involving the parasympa-
thetic nervous system are the best studied component of the
nasal nervous system and contribute to multiple forms of
rhinitis. Stimulation of the trigeminal nerve sends inputs to
the midbrain, where parasympathetic impulses originate, and
subsequently move to the nose via the preganglionic fibers
(superior salivary nucleus, CN VII through facial genu,
greater petrosal, vidian), where they synapse in the pterygopal-
atine ganglion. Postganglionic nerves travel with branches of the
nasopalatine nerve to the minor salivary glands in the nose.
Acetylcholine is released from the postganglionic
nerves and stimulates muscarinic receptors on the glands.
There are 5 muscarinic receptor subtypes, labeled M1 to M5.
M1, M2, and M3 receptors are found on glands, arteries,
veins, and epithelium. M4 receptors are found on arteries, and
M5 receptors are found on glands and arteries. M3 is the most
common receptor subtype.1 M1, M3, and M5 couple to
inositol polyphosphate, whereas M2 and M4 inhibit the
generation of cAMP.2 In addition to secreting acetylcholine,
postganglionic fibers release vasoactive intestinal peptide,
peptide histidine methionine, and peptide histidine valine.
Postganglionic nerve bodies also contain nitric oxide syn-
thase. These latter substances may be responsible for atro-
pine-resistant vasodilatation associated with parasympathetic
stimulation.
Anticholinergic agents block the binding of acetylcho-
line to the muscarinic receptors. The drugs can be delivered
topically or systemically. Methacholine challenges of the
nasal mucosa, which stimulates the gland directly via mus-
carinic receptors, have been used to show the effectiveness
and duration of the action of anticholinergic drugs.3,4
ROLE OF PARASYMPATHETIC GLANDULAR
SYSTEM IN NASAL PHYSIOLOGY
A major function of the nose is to warm and humidify
inspired air. The role of glandular secretion in this process
and subsequently the effect of blocking glandular stimulation
are not fully understood.
In a study by Ingelstedt and Ivstan, the effect of
atropine on humidification of air in the nose was studied by
psychrometer.5 They showed that a subcutaneous injection of
1 mg atropine greatly impaired the humidifying capacity of
the nose in healthy subjects. The authors concluded that
atropine-inhibitable glandular secretions provide the major
source of water for humidification. A criticism of this study
was that air was blown from the nasopharynx and measured
as it exited the nostril, the direction being the reverse of that
by which air is normally humidified. Kumlien and Drettner6
measured nasal conditioning in 16 healthy volunteers on 2
separate visits, the first visit without medication and the other
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visit after application of 0.06 mg of ipratropium bromide into
one nostril. There were no significant differences in nasal
conditioning between the 2 visits. Consistent with Kumlien
and Drettner’s finding, we showed no significant differences
in nasal conditioning after administration of ipratropium
bromide at a flow rate of 5 liter/min7 and normal saline. Our
studies, however, showed that with the use of ipratropium
bromide at flow rates of 10 and 20 liters/min, such as occur
with mild to moderate exercise, led to more water evapora-
tion and conditioning. Thus, we have shown that ipratropium
bromide, which is effective for the treatment of rhinorrhea,
increased the ability of the nose to condition air. This effect
is probably related to an increase in superficial nasal mucosal
blood flow rather than to changes in nasal volume. Our results
clearly indicate that blocking of the nasal glands does not
impair the ability of the nose to warm and humidify air,
suggesting that there are other sources providing fluid for the
humidification process and emphasizing the complex responses
of a physiologic system like the nose that cannot be predicted a
priori. The information that ipratropium bromide does not
impair nasal conditioning is useful clinically in the treatment
of patients who have rhinorrhea and asthma, because this
agent leads to better-conditioned air and thus does not ad-
versely affect the lower airway.
ANTICHOLINERGIC DRUGS IN RHINITIS
The involvement of the parasympathetic nervous sys-
tem has been shown to have an effect on multiple nasal
diseases. Georgitis showed that atropine sulfate, a nonselec-
tive muscarinic receptor antagonist, improved severe rhinor-
rhea in patients with perennial allergic rhinitis, whereas the
other nasal symptoms were not improved significantly.8
Georgitis reported similar results for treatment with ipratro-
pium, a nonselective muscarinic antagonist, in patients with
perennial allergic rhinitis.9 Kaiser and colleagues studied 176
patients who had perennial allergic rhinitis and found that 42
and 84 g/nostril of ipratropium bromide 3 times a day were
equally effective in reducing the severity and duration of
rhinorrhea compared with placebo, while resulting in no
significant effect on sneezing or congestion.10 Mygind and
Borum showed in a double-blind, placebo-controlled, cross-
over trial in 20 subjects who had severe chronic perennial
rhinitis with watery discharge as the dominant symptom that
ipratropium, 80 g 4 times a day, reduced rhinorrhea with no
effect on blockage or sneezing.11 Bonadonna and colleagues
showed the effectiveness of 80 g 2 times a day of ipratro-
pium nasal spray on cold-induced rhinorrhea and tissue
weights in skiers with and without allergies.12 Silvers showed
the effect of a single dose of 0.005% solution of atropine
sulfate on the rhinorrhea induced by skiing.13 Ostberg and
colleagues showed that 400 g 4 times a day of ipratropium
bromide reduced nose blowing by 56% and the amount of
blown secretions collected on tissues by 58% compared with
placebo in subjects who had a common cold, suggesting that
nearly 60% of the discharge in the first days of a cold are
reflex-mediated.14 Similar findings were obtained by Hayden
and colleagues.15 Ipratropium bromide nasal 0.06% was
shown to have beneficial effects on all nasal symptoms in an
open study of children 2 to 5 years old who had rhinorrhea
secondary to a common cold or allergy.16
Anticholinergics have been combined with other topi-
cal agents in the treatment of perennial rhinitis. Dockhorn and
colleagues reported on the use of 42 g 2 times a day of
ipratropium bromide nasal spray 0.03% combined with be-
clomethasone 84 g per nostril 2 times a day versus either
agent alone.17 Mixed matching placebos were used. After a
run-in period, each agent was compared with placebo; then
after 4 weeks, they evaluated the combination of both thera-
pies. Five hundred thirty-three patients, 279 allergic 274
nonallergic, ages 8 to 75 years were included. To enter, each
subject had to have mild rhinorrhea 2 hours per day for a
week plus mild congestion or sneezing. A negative Water’s
radiograph was required. Ipratropium alone had a faster onset
of action. Beclomethasone was more effective at reducing
congestion and sneezing. The investigators found that the
combination was more effective than either agent alone or
vehicle in reducing rhinorrhea. Ipratropium was more effec-
tive than placebo in previous nonsteroid responders. Unfor-
tunately, the results for the subgroups of allergic and nonal-
lergic rhinitis subjects were not shown.
Eccles and colleagues showed that the combination of
ipratropium and xylometazoline was effective for the treat-
ment of upper respiratory tract infections.18 Ipratropium re-
duced the rhinorrhea, whereas xylometazoline blocked the
congestion.
Finn and colleagues19 showed that terfenadine, 60 mg 2
times a day, plus ipratropium nasal spray 0.03% (42 g) 3
times a day was more effective than terfenadine plus vehicle
in the control of the severity and duration of rhinorrhea in
subjects with perennial rhinitis (n  91 nonallergic rhinitis;
n  114 perennial allergic rhinitis; results not broken down
by group). First-generation antihistamines have anticholin-
ergic activity. However, there are no clinical data showing
their effectiveness in vasomotor rhinitis.20
CHALLENGE STUDIES
Cruz showed the effect of atropine on cold, dry air
challenge of the upper airway.21 In support of the lack of
effect of anticholinergic agents on congestion, Shusterman
and colleagues studied the response to chlorine gas.22 In
allergic subjects, chlorine gas, an irritant, caused congestion,
more so in allergic individuals than in controls, but this was
unaffected by treatment with ipratropium bromide, 0.06%. In
contrast to most studies, McLean and colleagues showed that
ammonia increased nasal airway resistance in nonallergic
rhinitic subjects and that atropine inhibited the response.23
Most other studies suggest that anticholinergics have little or
no effect on congestion and its surrogate markers.
Stjarne and colleagues showed that both capsaicin and
nicotine stimulation led to reflex cholinergic activity, which
was blocked by atropine.24 They found that the patients with
vasomotor rhinitis who had rhinorrhea as a predominant
symptom were more responsive, suggesting that vasomotor
rhinitis patients could be divided into 2 groups based on their
symptoms.
WAO Journal • August 2009 Anticholinergic Drugs in Nonallergic Rhinitis
© 2009 World Allergy Organization 163
Reflex activation of nasal glands and hence rhinorrhea
can be initiated outside the nasal cavity, an example being
gustatory rhinitis.25 Pretreatment with atropine significantly
blocked rhinorrhea and secretions induced by a positive
food-induced challenge. Likewise, reflexes initiated in the
nose can affect the eyes and the bronchial tree.26
ADVERSE EFFECTS
The most frequent nasal adverse events of ipratropium
bromide were transient nasal dryness or epistaxis. No evi-
dence of rebound was reported after discontinuing usage of
the drug.27
Less than 20% of a single dose of ipratropium bromide
is absorbed from the nasal mucosa. Rare cases of systemic
anticholinergic effects, such as dry mouth, ocular irritation,
and blurred vision, have been reported.27
OTHER TREATMENTS AFFECTING THE
PARASYMPATHETIC NERVOUS SYSTEM
Botulinum toxin type A inhibits the release of acetyl-
choline from cholinergic nerve endings. Kim and colleagues
performed a double-blind, placebo-controlled study in which
they administered 2 units of botulinum toxin A into both
inferior and middle turbinates of patients who had intrinsic
rhinitis.28 This produced a significant reduction in rhinorrhea
(24–42%) and a 54% reduction in tissue usage, with no effect
on sneezing or nasal stuffiness. The positive effect lasted 4
weeks. Intrinsic rhinitis was defined by history, negative skin
or RAST tests, negative history of asthma or dermatitides,
and no satisfactory response to treatment with an antihista-
mine or topical nasal steroid.
Besides blocking the central parasympathetic reflex
after the release of acetylcholine, investigators have used
capsaicin to deplete c-fibers of neuropeptides, reducing both
the initiation of the central reflex and nasal hyperreactivity.
Desensitization with capsaicin led to clinical improvement
in patients who had vasomotor rhinitis and rhinorrhea.29
Others have used silver nitrate or lasers to affect surface
secretions.30,31
Vidian neurectomy has also been used; however, side
effects of dry eyes and recurrence of symptoms possibly
related to reinnervation can occur, making this a rarely
performed procedure.32–34 This technique blocks more than
the effects of acetylcholine and has effects on neuropeptide
release and axonal reflexes.
CONCLUSIONS
Anticholinergic drugs are effective in blocking para-
sympathetic-induced release of acetylcholine, which plays a
role in the symptom of watery rhinorrhea in many forms of
rhinitis. Ipratropium bromide is approved for the treatment of
rhinorrhea associated with allergic and nonallergic rhinitis.
Criteria for selecting responders are based primarily on symp-
tom assessment. Knowing the response to prior treatments
helps choose responders to ipratropium bromide.
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